urea/inflammation

1. FIELD OF THE INVENTION The present invention relates to novel carbamates, ureas, and pharmaceutically acceptable salts thereof; compositions comprising the carbamate, urea, or a pharmaceutically acceptable salt thereof; and methods for treating or preventing cancer, inflammation, or a viral

FIELD OF THE INVENTION This invention relates generally to N-adamant-1-yl-N'-[4-chlorobenzothiazol-2-yl] urea, pharmaceutical compositions comprising the same, and methods of using the same in the treatment of inflammation and as an anticancer radiosensitizing agent. BACKGROUND OF THE INVENTION The

BACKGROUND OF THE PRESENT INVENTION The present invention is novel compounds, which are derivatives of hydroxybenzylamine and as such are related to capsaicin. The present compounds have antiinflammatory activity for the treatment of arthritis, asthma, Raynaud's disease, inflammatory bowel

CROSS-REFERENCE TO RELATED APPLICATIONS This application is filed pursuant to 35 USC 371 as a United States National Phase Application of International Patent Application Serial No. PCT/EP03/03345 filed on 27 Mar. 2003, which claims priority from GB 0207432.6 filed on 28 Mar. 2002 in the United

CROSS-REFERENCE TO RELATED APPLICATIONS This application is filed pursuant to 35 USC 371 as a United States National Phase Application of International Patent Application Serial No. PCT/EP03/03335 filed on 27 Mar. 2003, which claims priority from GB 0207434.2 filed on 28 Mar. 2002 and GB 0301608.6

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Patent Application No. PCT/JP2016/002557 filed May 26, 2016, which claims priority from Japanese Patent Application No. 2015-107227 filed May 27, 2015, the disclosures of each of which are incorporated

The invention relates to heterocyclylcarbonyl substituted benzofuranyl-ureas, processes for their preparation and their use in medicaments. It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which

The invention relates to N-(3-benzofuranyl)urea-derivatives, processes for their preparation and their use in medicaments. It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which are important in

The invention relates to N-(3-benzofuranyl)urea-derivatives, processes for their preparation and their use in medicaments. It is known that the NADPH oxidase of phagocytes is the physiological source to the superoxide radical anion and reactive oxygen species derived therefrom which are important in

FIELD OF THE INVENTION The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising

FIELD OF THE INVENTION The present invention relates to 1-(N-substituted aryl)-1-N-(2-substituted pyrimidin-4-yl)-3-N-(alkyl or substituted alkyl) ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the

BACKGROUND OF THE INVENTION The present invention concerns pharmaceutical compositions which include urea and hyaluronic acid or derivatives of hyaluronic acid. The present invention further concerns methods of treating disease of the cutis, anorectal epithelium and rectal mucosa employing the